AbCellera Biologics Inc. Common Shares
Here’s whether AbCellera Biologics Inc. Common Shares (ABCL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+4.99% over 10 days); 3-month momentum positive (+27.9%). Concerns: below the 50-day MA (medium-term momentum negative); RSI 20 — oversold; declining volume on rally — weak conviction (0.69x 30d avg). Currently 37.1% off its 52-week high. Score: +1/7.
ABCL is holding above its long-term 200-day MA ($4.49) but has slipped below the 50-day MA ($5.96), pointing to short-term weakness in an otherwise intact trend. An RSI of 20.4 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +5.8% compares to +16.5% for SPY (trailed the market by 10.7%). The current 37.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.